Comparison	O
of	O
the	O
Effect	O
of	O
Velvet	O
Antler	O
from	O
Different	O
Sections	O
on	O
Longitudinal	O
Bone	O
Growth	O
of	O
Adolescent	O
Rats	B-OG

Academic	O
Editor	O
:	O
Yuewen	O
Gong	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
velvet	O
antler	O
(	O
VA	O
)	O
from	O
different	O
sections	O
for	O
promoting	O
longitudinal	O
bone	O
growth	O
in	O
growing	O
rats	B-OG
.	O

VA	O
was	O
divided	O
into	O
upper	O
(	O
VAU	O
),	O
middle	O
(	O
VAM	O
),	O
and	O
basal	O
sections	O
(	O
VAB	O
).	O

An	O
in	O
vivo	O
study	O
was	O
performed	O
to	O
examine	O
the	O
effect	O
on	O
longitudinal	O
bone	O
growth	O
in	O
adolescent	O
rats	B-OG
.	O

In	O
addition	O
,	O
in	O
vitro	O
osteogenic	O
activities	O
were	O
examined	O
using	O
osteoblastic	O
MG	O
-	O
63	O
cells	O
.	O

VA	O
promoted	O
longitudinal	O
bone	O
growth	O
and	O
height	O
of	O
the	O
growth	O
plate	O
in	O
adolescent	O
rats	B-OG
.	O

Bone	B-GP
morphogenetic	I-GP
protein	I-GP
-	I-GP
2	I-GP
(	O
BMP	B-GP
-	I-GP
2	I-GP
)	O
in	O
growth	O
plate	O
of	O
VA	O
group	O
was	O
highly	O
expressed	O
compared	O
with	O
control	O
.	O

The	O
anabolic	O
effect	O
of	O
VA	O
on	O
bone	O
was	O
further	O
supported	O
by	O
in	O
vitro	O
study	O
.	O

VA	O
enhanced	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
mineralization	O
of	O
MG	O
-	O
63	O
cells	O
.	O

The	O
mRNA	O
expressions	O
of	O
osteogenic	O
genes	O
such	O
as	O
collagen	B-GP
,	O
alkaline	B-GP
phosphatase	I-GP
,	O
and	O
osteocalcin	B-GP
were	O
increased	O
by	O
VA	O
treatment	O
.	O

These	O
effects	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
study	O
were	O
decreased	O
from	O
upper	O
to	O
basal	O
sections	O
of	O
VA	O
.	O

In	O
conclusion	O
,	O
VA	O
treatment	O
promotes	O
longitudinal	O
bone	O
growth	O
in	O
growing	O
rats	B-OG
through	O
enhanced	O
BMP	B-GP
-	I-GP
2	I-GP
expression	O
,	O
osteogenic	O
activities	O
,	O
and	O
bone	O
matrix	O
gene	O
expressions	O
.	O

In	O
addition	O
,	O
present	O
study	O
provides	O
evidence	O
for	O
the	O
regional	O
differences	O
in	O
the	O
effectiveness	O
of	O
velvet	O
antler	O
for	O
longitudinal	O
bone	O
growth	O
.	O

1	O
.	O

Introduction	O

Longitudinal	O
bone	O
growth	O
,	O
which	O
determines	O
the	O
size	O
and	O
shape	O
of	O
the	O
body	O
frame	O
,	O
proceeds	O
at	O
a	O
rate	O
distinct	O
from	O
that	O
of	O
muscle	O
and	O
other	O
tissues	O
and	O
is	O
controlled	O
by	O
specific	O
mechanisms	O
.	O

During	O
childhood	O
and	O
adolescence	O
,	O
the	O
long	O
bones	O
grow	O
at	O
the	O
ends	O
of	O
the	O
bones	O
which	O
occur	O
at	O
the	O
growth	O
plate	O
by	O
endochondral	O
ossification	O
of	O
epiphyseal	O
plate	O
[	O
1	O
].	O

Growth	O
plate	O
chondrocyte	O
proliferation	O
and	O
hypertrophy	O
lead	O
to	O
formation	O
of	O
new	O
cartilage	O
,	O
chondrogenesis	O
,	O
and	O
remodeling	O
of	O
the	O
newly	O
formed	O
cartilage	O
into	O
bone	O
tissue	O
resulting	O
in	O
longitudinal	O
bone	O
growth	O
[	O
2	O
].	O

The	O
current	O
methods	O
for	O
increasing	O
final	O
height	O
include	O
treatment	O
with	O
a	O
growth	B-GP
hormone	I-GP
alone	O
or	O
in	O
combination	O
with	O
an	O
analog	O
of	O
gonadotropin	B-GP
-	I-GP
releasing	I-GP
hormone	I-GP
[	O
3	O
].	O

However	O
,	O
it	O
is	O
generally	O
too	O
expensive	O
and	O
also	O
has	O
harmful	O
side	O
effects	O
such	O
as	O
prepubertal	O
gynecomastia	B-DS
,	O
arthralgia	O
,	O
edema	O
,	O
benign	B-DS
intracranial	I-DS
hypertension	I-DS
,	O
insulin	O
resistance	O
,	O
and	O
leukemia	B-DS
[	O
4	O
].	O

On	O
that	O
account	O
,	O
there	O
has	O
been	O
an	O
increasing	O
awareness	O
of	O
the	O
benefits	O
of	O
natural	O
products	O
,	O
and	O
many	O
plant	B-OG
-	O
derived	O
medicines	O
have	O
been	O
reported	O
.	O

However	O
,	O
the	O
researches	O
on	O
animal	B-OG
medicines	O
or	O
functional	O
foods	O
are	O
still	O
relatively	O
few	O
,	O
although	O
animal	B-OG
medicines	O
have	O
been	O
proven	O
of	O
various	O
important	O
components	O
,	O
such	O
as	O
proteins	O
,	O
peptides	O
,	O
fatty	O
acids	O
,	O
glycosaminoglycans	O
,	O
prostaglandins	O
,	O
vitamins	O
,	O
minerals	O
,	O
dietary	O
fiber	O
,	O
essential	O
oils	O
,	O
and	O
carotenoids	O
[	O
5	O
,	O
6	O
],	O
which	O
can	O
be	O
used	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
various	O
diseases	O
.	O

Velvet	O
antler	O
(	O
VA	O
),	O
the	O
immature	O
antler	O
of	O
male	O
deer	B-OG
,	O
is	O
traditionally	O
used	O
for	O
thousands	O
of	O
years	O
in	O
Asian	O
countries	O
,	O
such	O
as	O
Korea	O
,	O
China	O
,	O
Taiwan	O
,	O
and	O
Mongolia	O
.	O

It	O
is	O
currently	O
estimated	O
that	O
the	O
global	O
production	O
of	O
velvet	O
antlers	O
is	O
near	O
to	O
1300	O
tons	O
/	O
year	O
,	O
which	O
is	O
still	O
rapidly	O
growing	O
to	O
meet	O
the	O
requirements	O
of	O
medicinal	O
markets	O
[	O
7	O
].	O

As	O
a	O
typical	O
traditional	O
animal	B-OG
medicine	O
,	O
VA	O
has	O
pharmacological	O
effects	O
to	O
improve	O
immune	O
system	O
,	O
physical	O
strength	O
,	O
and	O
sexual	O
function	O
[	O
7	O
,	O
8	O
].	O

VA	O
,	O
also	O
,	O
has	O
been	O
reported	O
to	O
possess	O
bone	O
strengthening	O
activity	O
and	O
has	O
been	O
used	O
in	O
treating	O
arthritis	B-DS
,	O
osteoporosis	B-DS
,	O
and	O
fracture	O
in	O
animal	B-OG
model	O
or	O
human	B-OG
clinical	O
trials	O
[	O
9	O
â€“	O
12	O
].	O

A	O
whole	O
VA	O
stick	O
is	O
usually	O
divided	O
into	O
four	O
portions	O
,	O
with	O
the	O
value	O
decreasing	O
from	O
the	O
tip	O
to	O
the	O
base	O
.	O

Chemical	O
analyses	O
of	O
VA	O
revealed	O
that	O
there	O
are	O
regional	O
differences	O
in	O
chemical	O
composition	O
:	O
the	O
contents	O
of	O
proteins	O
and	O
lipids	O
decrease	O
downward	O
from	O
the	O
tip	O
to	O
the	O
base	O
,	O
while	O
those	O
of	O
ash	O
,	O
calcium	O
,	O
and	O
collagen	B-GP
increase	O
[	O
13	O
]	O
suggesting	O
the	O
degree	O
of	O
calcification	O
increased	O
from	O
tip	O
to	O
base	O
section	O
of	O
VA	O
.	O

During	O
the	O
ossification	O
of	O
deer	B-OG
antler	O
,	O
the	O
total	O
collagen	B-GP
content	O
was	O
found	O
to	O
be	O
increased	O
.	O

Typically	O
,	O
the	O
antler	O
is	O
cut	O
off	O
near	O
the	O
base	O
after	O
it	O
is	O
about	O
two	O
-	O
thirds	O
of	O
its	O
potential	O
full	O
size	O
,	O
between	O
55	O
and	O
65	O
days	O
of	O
growth	O
,	O
before	O
any	O
significant	O
calcification	O
occurs	O
.	O

Traditionally	O
,	O
the	O
market	O
values	O
of	O
antlers	O
are	O
downgraded	O
with	O
increasing	O
degree	O
of	O
calcification	O
.	O

However	O
,	O
which	O
parts	O
of	O
VA	O
are	O
suitable	O
for	O
preventing	O
and	O
managing	O
bone	O
health	O
especially	O
bone	O
growth	O
had	O
not	O
been	O
clarified	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
VA	O
from	O
different	O
sections	O
on	O
longitudinal	O
bone	O
growth	O
of	O
adolescent	O
rats	B-OG
and	O
elucidate	O
the	O
underlying	O
mechanisms	O
for	O
the	O
effect	O
.	O

2	O
.	O

Materials	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Materials	O

VA	O
,	O
obtained	O
from	O
farmed	O
Elk	B-OG
deer	I-OG
75	O
days	O
after	O
casting	O
,	O
was	O
kindly	O
provided	O
by	O
the	O
Animal	B-OG
Genetic	O
Resources	O
Station	O
(	O
National	O
Institute	O
of	O
Animal	B-OG
Science	O
,	O
South	O
Korea	O
).	O

VA	O
was	O
divided	O
into	O
upper	O
(	O
VAU	O
),	O
middle	O
(	O
VAM	O
),	O
and	O
basal	O
(	O
VAB	O
)	O
sections	O
(	O
Figure	O
1	O
).	O

The	O
criteria	O
used	O
for	O
dividing	O
the	O
antler	O
into	O
three	O
sections	O
is	O
defined	O
as	O
follows	O
:	O
upper	O
section	O
,	O
top	O
15	O
cm	O
of	O
the	O
part	O
of	O
the	O
main	O
beam	O
to	O
the	O
2nd	O
division	O
of	O
a	O
deer	B-OG
'	O
s	O
antlers	O
from	O
its	O
head	O
;	O
middle	O
section	O
,	O
the	O
upper	O
half	O
of	O
the	O
remaining	O
main	O
beam	O
;	O
and	O
base	O
section	O
,	O
the	O
lower	O
half	O
of	O
the	O
remaining	O
main	O
beam	O
.	O

Total	O
part	O
of	O
each	O
section	O
was	O
sliced	O
with	O
a	O
bone	O
slicer	O
,	O
freeze	O
-	O
dried	O
,	O
and	O
ground	O
into	O
powder	O
.	O

The	O
powdered	O
VA	O
was	O
immersed	O
in	O
70	O
%	O
ethanol	O
for	O
3	O
days	O
,	O
filtered	O
,	O
concentrated	O
by	O
vacuum	O
evaporation	O
,	O
and	O
finally	O
subjected	O
to	O
freeze	O
drying	O
.	O

Respective	O
yields	O
of	O
sections	O
,	O
from	O
upper	O
to	O
basal	O
,	O
were	O
3	O
.	O
4	O
%	O
(	O
VAU	O
),	O
2	O
.	O
9	O
%	O
(	O
VAM	O
),	O
and	O
1	O
.	O
7	O
%	O
(	O
VAB	O
).	O

2	O
.	O
2	O
.	O

Animals	B-OG

Longitudinal	O
bone	O
growth	O
was	O
determined	O
in	O
3	O
-	O
week	O
-	O
old	O
male	O
Sprague	B-OG
-	I-OG
Dawley	I-OG
rats	I-OG
(	O
Samtako	O
Co	O
.,	O
Osan	O
,	O
Korea	O
).	O

The	O
experimental	O
procedures	O
were	O
performed	O
in	O
accordance	O
with	O
protocols	O
approved	O
by	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
,	O
Semyung	O
University	O
(	O
smecae	O
15	O
-	O
09	O
-	O
01	O
).	O

The	O
animals	B-OG
were	O
housed	O
under	O
controlled	O
temperature	O
and	O
lighting	O
conditions	O
.	O

The	O
rats	B-OG
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
n	O
=	O
8	O
);	O
vehicle	O
(	O
control	O
,	O
distilled	O
water	O
)	O
and	O
upper	O
(	O
VAU	O
),	O
middle	O
(	O
VAM	O
),	O
and	O
basal	O
(	O
VAB	O
)	O
sections	O
of	O
antler	O
extract	O
(	O
100	O
mg	O
/	O
kg	O
)	O
were	O
orally	O
administered	O
daily	O
via	O
stomach	O
tube	O
for	O
5	O
consecutive	O
days	O
.	O

Treatment	O
dose	O
was	O
decided	O
from	O
the	O
preliminary	O
study	O
.	O

On	O
the	O
sixth	O
day	O
,	O
all	O
rats	B-OG
were	O
sacrificed	O
under	O
chloral	O
hydrate	O
anesthesia	O
for	O
tissue	O
analysis	O
.	O

2	O
.	O
3	O
.	O

Measurement	O
of	O
Longitudinal	O
Bone	O
Growth	O

To	O
measure	O
the	O
effect	O
on	O
longitudinal	O
bone	O
growth	O
rate	O
,	O
calcein	O
was	O
used	O
as	O
a	O
fluorescence	O
marker	O
to	O
label	O
the	O
bone	O
line	O
on	O
the	O
surface	O
of	O
the	O
tibia	O
.	O

Calcein	O
plays	O
the	O
role	O
of	O
fluorescent	O
dye	O
under	O
ultraviolet	O
illumination	O
.	O

Calcein	O
(	O
10	O
mg	O
/	O
kg	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
was	O
injected	O
intraperitoneally	O
24	O
h	O
before	O
sacrifice	O
.	O

The	O
dissected	O
tibias	O
were	O
fixed	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
buffered	O
formalin	O
for	O
2	O
h	O
,	O
decalcified	O
,	O
and	O
dehydrated	O
by	O
immersing	O
in	O
30	O
%	O
sucrose	O
for	O
1	O
day	O
at	O
4	O
Â°	O
C	O
.	O

Dehydrated	O
bone	O
was	O
sectioned	O
longitudinally	O
at	O
sagittal	O
sections	O
of	O
proximal	O
part	O
with	O
a	O
thickness	O
of	O
40	O
Î¼m	O
using	O
a	O
sliding	O
microtome	O
(	O
HM440E	O
,	O
Zeiss	O
,	O
Germany	O
).	O

Bone	O
growth	O
was	O
measured	O
by	O
measuring	O
the	O
gap	O
between	O
fluorescent	O
line	O
formed	O
by	O
calcein	O
and	O
the	O
epiphyseal	O
end	O
line	O
of	O
the	O
growth	O
plate	O
at	O
three	O
different	O
locations	O
using	O
a	O
fluorescent	O
microscope	O
(	O
BX60	O
,	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
),	O
and	O
the	O
averages	O
were	O
obtained	O
.	O

2	O
.	O
4	O
.	O

Measurement	O
of	O
Growth	O
Plate	O
Height	O

Cresyl	O
violet	O
staining	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
used	O
to	O
stain	O
the	O
chondrocytes	O
in	O
the	O
growth	O
plate	O
of	O
the	O
samples	O
.	O

Each	O
tibia	O
sample	O
was	O
sectioned	O
longitudinally	O
at	O
a	O
thickness	O
of	O
40	O
Î¼m	O
using	O
a	O
sliding	O
microtome	O
as	O
described	O
above	O
and	O
stained	O
with	O
cresyl	O
violet	O
.	O

The	O
growth	O
plate	O
height	O
was	O
measured	O
at	O
three	O
different	O
locations	O
and	O
the	O
averages	O
were	O
obtained	O
.	O

2	O
.	O
5	O
.	O

Bone	B-GP
Morphogenetic	I-GP
Protein	I-GP
-	I-GP
2	I-GP
Expression	O

For	O
the	O
detection	O
of	O
bone	B-GP
morphogenetic	I-GP
protein	I-GP
-	I-GP
2	I-GP
(	O
BMP	B-GP
-	I-GP
2	I-GP
)	O
in	O
the	O
growth	O
plate	O
,	O
the	O
dehydrated	O
tibia	O
sections	O
were	O
incubated	O
overnight	O
in	O
1	O
%	O
Triton	O
X	O
-	O
100	O
containing	O
goat	B-OG
BMP	B-GP
-	I-GP
2	I-GP
antibody	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
diluted	O
1	O
:	O
500	O
)	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
sections	O
were	O
incubated	O
with	O
anti	O
-	O
goat	B-OG
antibody	B-GP
(	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
CA	O
,	O
USA	O
,	O
diluted	O
1	O
:	O
200	O
)	O
for	O
60	O
min	O
and	O
stained	O
with	O
0	O
.	O
05	O
%	O
3	O
,	O
3	O
-	O
diaminobenzidine	O
(	O
Sigma	O
Chemical	O
Co	O
.)	O
containing	O
0	O
.	O
03	O
%	O
hydrogen	O
peroxide	O
.	O

2	O
.	O
6	O
.	O

Cell	O
Culture	O

Human	B-OG
osteoblast	O
-	O
like	O
MG	O
-	O
63	O
cells	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
).	O

Cells	O
were	O
cultured	O
at	O
37	O
Â°	O
C	O
in	O
a	O
5	O
%	O
CO2	O
atmosphere	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
(	O
DMEM	O
,	O
Gibco	O
,	O
MD	O
,	O
USA	O
)	O
containing	O
10	O
%	O
heat	O
-	O
inactivated	O
FBS	O
(	O
Invitrogen	O
,	O
Grand	O
island	O
,	O
NY	O
,	O
USA	O
)	O
and	O
100	O
U	O
/	O
mL	O
penicillin	O
/	O
streptomycin	O
(	O
Sigma	O
-	O
Aldrich	O
).	O

Bone	O
marrow	O
cells	O
prepared	O
from	O
the	O
femur	O
of	O
male	O
ICR	O
mice	B-OG
were	O
cultured	O
in	O
Î±	O
-	O
modified	O
minimal	O
essential	O
medium	O
(	O
Î±	O
-	O
MEM	O
,	O
Gibco	O
)	O
containing	O
10	O
%	O
heat	O
-	O
inactivated	O
FBS	O
.	O

After	O
3	O
days	O
of	O
culture	O
,	O
floating	O
cells	O
were	O
removed	O
and	O
attached	O
cells	O
were	O
used	O
as	O
osteoclast	O
precursors	O
.	O

2	O
.	O
7	O
.	O

Osteoblasts	O
Proliferation	O

The	O
effects	O
of	O
VA	O
from	O
different	O
sections	O
on	O
proliferation	O
of	O
MG	O
-	O
63	O
cell	O
were	O
determined	O
by	O
a	O
colorimetric	O
immunoassay	O
kit	O
(	O
Roche	O
Diagnostics	O
,	O
Mannheim	O
,	O
Germany	O
)	O
which	O
is	O
based	O
on	O
quantitating	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
incorporation	O
into	O
the	O
newly	O
synthesized	O
DNA	O
of	O
replicating	O
cells	O
.	O

MG	O
-	O
63	O
cells	O
were	O
seeded	O
(	O
5	O
,	O
000	O
cells	O
/	O
well	O
)	O
in	O
96	O
-	O
well	O
plates	O
containing	O
DMEM	O
with	O
10	O
%	O
FBS	O
and	O
allowed	O
to	O
adhere	O
overnight	O
.	O

The	O
media	O
were	O
replaced	O
with	O
DMEM	O
containing	O
VA	O
samples	O
(	O
10	O
,	O
50	O
,	O
and	O
100	O
Î¼g	O
/	O
mL	O
)	O
and	O
incubated	O
for	O
24	O
h	O
.	O

Subsequently	O
,	O
BrdU	O
was	O
added	O
to	O
each	O
well	O
and	O
reincubated	O
for	O
2	O
h	O
.	O

After	O
14	O
h	O
of	O
incubation	O
at	O
37	O
Â°	O
C	O
,	O
labeling	O
media	O
was	O
removed	O
,	O
cells	O
were	O
fixed	O
,	O
and	O
the	O
cells	O
with	O
BrdU	O
label	O
in	O
the	O
DNA	O
were	O
located	O
with	O
peroxidase	B-GP
-	O
conjugated	O
anti	O
-	O
BrdU	O
antibody	B-GP
solution	O
.	O

Then	O
bound	O
anti	O
-	O
BrdU	O
with	O
substrate	O
was	O
colorimetrically	O
measured	O
with	O
a	O
microplate	O
reader	O
(	O
BioTek	O
Inc	O
.,	O
Winooski	O
,	O
VT	O
,	O
USA	O
)	O
at	O
450	O
nm	O
.	O

2	O
.	O
8	O
.	O

Alkaline	B-GP
Phosphatase	I-GP
Activity	O

Alkaline	B-GP
phosphatase	I-GP
(	O
ALP	B-GP
)	O
activity	O
was	O
measured	O
using	O
enzymatic	O
assay	O
.	O

MG	O
-	O
63	O
cells	O
,	O
incubated	O
in	O
DMEM	O
,	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
(	O
50	O
,	O
000	O
cells	O
/	O
well	O
)	O
and	O
incubated	O
for	O
24	O
h	O
.	O

The	O
medium	O
was	O
changed	O
to	O
osteogenic	O
medium	O
(	O
DMEM	O
with	O
10	O
mM	O
Î²	O
-	O
glycerophosphate	O
,	O
5	O
nM	O
dexamethasone	O
,	O
and	O
50	O
Î¼g	O
/	O
mL	O
ascorbic	O
acid	O
);	O
VA	O
samples	O
(	O
50	O
and	O
100	O
Î¼g	O
/	O
mL	O
)	O
were	O
added	O
to	O
the	O
cells	O
and	O
incubated	O
for	O
another	O
24	O
h	O
.	O

The	O
50	O
and	O
100	O
Î¼g	O
/	O
mL	O
concentrations	O
were	O
chosen	O
since	O
the	O
maximum	O
effect	O
and	O
plateau	O
had	O
been	O
gained	O
under	O
those	O
two	O
concentrations	O
in	O
cell	O
proliferation	O
assay	O
results	O
.	O

The	O
cells	O
were	O
then	O
rinsed	O
with	O
PBS	O
and	O
lysed	O
in	O
300	O
Î¼L	O
of	O
0	O
.	O
2	O
%	O
of	O
Triton	O
X	O
-	O
100	O
.	O

The	O
cell	O
lysates	O
were	O
centrifuged	O
at	O
13	O
,	O
000	O
rpm	O
for	O
5	O
min	O
.	O

The	O
supernatant	O
of	O
the	O
lysate	O
was	O
used	O
for	O
the	O
measurement	O
of	O
ALP	B-GP
activity	O
by	O
measuring	O
the	O
release	O
of	O
p	O
-	O
nitrophenol	O
from	O
p	O
-	O
nitrophenylphosphate	O
at	O
pH	O
9	O
.	O
8	O
.	O

2	O
.	O
9	O
.	O

Collagen	B-GP
Content	O

Collagen	B-GP
synthesis	O
was	O
measured	O
using	O
picrosirius	O
red	O
method	O
[	O
14	O
].	O

MG	O
-	O
63	O
cells	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
(	O
50	O
,	O
000	O
cells	O
/	O
well	O
)	O
and	O
allowed	O
to	O
adhere	O
overnight	O
.	O

The	O
medium	O
was	O
changed	O
to	O
osteogenic	O
medium	O
;	O
VA	O
samples	O
(	O
100	O
Î¼g	O
/	O
mL	O
)	O
were	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
7	O
days	O
.	O

Cells	O
were	O
fixed	O
with	O
Bouin	O
'	O
s	O
fluid	O
and	O
stained	O
with	O
0	O
.	O
1	O
%	O
Sirius	O
red	O
(	O
Direct	O
Red	O
80	O
,	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
a	O
saturated	O
aqueous	O
solution	O
of	O
picric	O
acid	O
for	O
30	O
min	O
.	O

Stained	O
dye	O
was	O
dissolved	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
540	O
nm	O
.	O

2	O
.	O
10	O
.	O

Calcium	O
Deposition	O

The	O
formation	O
of	O
calcium	O
phosphate	O
was	O
determined	O
by	O
alizarin	O
red	O
-	O
S	O
assay	O
[	O
15	O
].	O

MG	O
-	O
63	O
cells	O
were	O
seeded	O
and	O
incubated	O
as	O
described	O
above	O
in	O
the	O
collagen	B-GP
assay	O
process	O
.	O

After	O
7	O
days	O
,	O
cells	O
were	O
fixed	O
with	O
10	O
%	O
formaldehyde	O
and	O
stained	O
with	O
2	O
%	O
of	O
alizarin	O
red	O
-	O
S	O
(	O
pH	O
4	O
.	O
2	O
,	O
Sigma	O
-	O
Aldrich	O
)	O
at	O
room	O
temperature	O
.	O

The	O
stained	O
alizarin	O
red	O
-	O
S	O
was	O
extracted	O
with	O
10	O
%	O
acetic	O
acid	O
,	O
and	O
the	O
amount	O
of	O
calcium	O
deposition	O
was	O
quantified	O
using	O
the	O
absorbance	O
of	O
extracted	O
alizarin	O
red	O
-	O
S	O
at	O
405	O
nm	O
.	O

2	O
.	O
11	O
.	O

Real	O
-	O
Time	O
PCR	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
to	O
analyze	O
relative	O
gene	O
expression	O
.	O

MG	O
-	O
63	O
cells	O
were	O
seeded	O
in	O
6	O
-	O
well	O
plates	O
(	O
100	O
,	O
000	O
cells	O
/	O
well	O
)	O
and	O
allowed	O
to	O
adhere	O
overnight	O
.	O

The	O
medium	O
was	O
changed	O
to	O
osteogenic	O
medium	O
;	O
VA	O
sample	O
(	O
100	O
Î¼g	O
/	O
mL	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
24	O
h	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
RNeasy	O
Â®	O
Protect	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
),	O
and	O
cDNA	O
was	O
synthesized	O
from	O
mRNA	O
using	O
QuantiTect	O
Â®	O
Reverse	O
Transcription	O
Kit	O
(	O
Qiagen	O
).	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
using	O
QuantiTect	O
â„¢	O
SYBR	O
Â®	O
Green	O
PCR	O
Kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
PCR	O
primer	O
sequences	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Analyses	O
were	O
performed	O
using	O
Rotor	O
-	O
Gene	O
Q	O
Â®	O
(	O
Qiagen	O
)	O
and	O
gene	O
expression	O
values	O
were	O
calculated	O
based	O
on	O
the	O
comparative	O
Î”Î”CT	O
method	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

2	O
.	O
12	O
.	O

Osteoclastogenesis	O
Assay	O

For	O
induction	O
of	O
osteoclastogenesis	O
,	O
osteoclast	O
precursor	O
cells	O
prepared	O
as	O
described	O
above	O
were	O
further	O
cultured	O
for	O
4	O
days	O
with	O
RANKL	B-GP
(	O
50	O
ng	O
/	O
mL	O
)	O
and	O
M	B-GP
-	I-GP
CSF	I-GP
(	O
30	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
of	O
VA	O
samples	O
.	O

Osteoclasts	O
were	O
identified	O
by	O
staining	O
tartrate	B-GP
-	I-GP
resistant	I-GP
acid	I-GP
phosphatase	I-GP
(	O
TRAP	B-GP
),	O
a	O
marker	O
enzyme	O
of	O
osteoclasts	O
[	O
16	O
],	O
using	O
commercial	O
kit	O
(	O
TRAP	B-GP
387	O
-	O
A	O
Kit	O
,	O
Sigma	O
-	O
Aldrich	O
).	O

TRAP	B-GP
-	O
positive	O
multinucleated	O
cells	O
with	O
â‰¥	O
3	O
nuclei	O
were	O
counted	O
as	O
osteoclasts	O
.	O

2	O
.	O
13	O
.	O

Statistical	O
Analysis	O

The	O
data	O
were	O
expressed	O
as	O
mean	O
Â±	O
SD	O
.	O

One	O
-	O
way	O
ANOVA	O
followed	O
by	O
Tukey	O
'	O
s	O
multiple	O
comparison	O
test	O
was	O
performed	O
for	O
statistical	O
analysis	O
(	O
GraphPad	O
Prism	O
ver	O
.	O

6	O
),	O
and	O
P	O
values	O
of	O
less	O
than	O
0	O
.	O
05	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
indicated	O
significant	O
differences	O
.	O

All	O
in	O
vitro	O
experiments	O
were	O
performed	O
with	O
triplicate	O
independent	O
samples	O
.	O

3	O
.	O

Results	O
and	O
Discussion	O

3	O
.	O
1	O
.	O

Effects	O
on	O
Cell	O
Longitudinal	O
Bone	O
Growth	O

To	O
determine	O
the	O
growth	O
per	O
day	O
,	O
instead	O
of	O
the	O
total	O
growth	O
over	O
a	O
period	O
,	O
exact	O
methods	O
for	O
measurement	O
are	O
necessary	O
.	O

Recently	O
,	O
the	O
use	O
of	O
tetracycline	O
or	O
calcein	O
as	O
intravital	O
markers	O
of	O
the	O
growth	O
process	O
to	O
label	O
mineralizing	O
bone	O
in	O
the	O
rat	B-OG
has	O
been	O
reported	O
[	O
17	O
,	O
18	O
].	O

In	O
the	O
present	O
study	O
,	O
calcein	O
was	O
used	O
to	O
label	O
newly	O
formed	O
bone	O
for	O
the	O
determination	O
of	O
longitudinal	O
bone	O
growth	O
.	O

Calcein	O
binds	O
to	O
free	O
calcium	O
and	O
gets	O
deposited	O
in	O
newly	O
deposited	O
bone	O
,	O
causing	O
staining	O
and	O
fluorescence	O
under	O
ultraviolet	O
illumination	O
.	O

The	O
effects	O
of	O
the	O
different	O
sections	O
of	O
VA	O
on	O
the	O
rate	O
of	O
longitudinal	O
bone	O
growth	O
from	O
the	O
proximal	O
tibia	O
in	O
the	O
rat	B-OG
are	O
depicted	O
in	O
Figure	O
2	O
.	O

The	O
fluorescent	O
line	O
corresponds	O
to	O
the	O
injection	O
of	O
calcein	O
which	O
binds	O
with	O
calcium	O
in	O
the	O
newly	O
formed	O
bone	O
(	O
Figure	O
2	O
(	O
a	O
),	O
lower	O
arrow	O
).	O

The	O
arrow	O
between	O
the	O
fluorescent	O
line	O
formed	O
by	O
calcein	O
(	O
Figure	O
2	O
(	O
a	O
),	O
lower	O
arrow	O
)	O
and	O
epiphyseal	O
end	O
line	O
of	O
the	O
growth	O
plate	O
(	O
Figure	O
2	O
(	O
a	O
),	O
upper	O
arrow	O
)	O
indicates	O
the	O
length	O
of	O
the	O
bone	O
growth	O
during	O
24	O
h	O
period	O
.	O

Longitudinal	O
bone	O
growth	O
was	O
significantly	O
increased	O
by	O
VAU	O
treatment	O
compared	O
with	O
the	O
control	O
(	O
Figure	O
2	O
(	O
a	O
)).	O
Figure	O
2	O
(	O
b	O
)	O
shows	O
the	O
numerical	O
values	O
of	O
the	O
longitudinal	O
bone	O
growth	O
.	O

Longitudinal	O
bone	O
growth	O
in	O
control	O
rat	B-OG
was	O
617	O
.	O
4	O
Â±	O
34	O
.	O
2	O
Î¼m	O
/	O
day	O
,	O
and	O
administration	O
of	O
VAU	O
significantly	O
increased	O
the	O
longitudinal	O
bone	O
growth	O
to	O
718	O
.	O
6	O
Â±	O
48	O
.	O
6	O
Î¼m	O
/	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

VAU	O
,	O
VAM	O
,	O
and	O
VAB	O
caused	O
16	O
.	O
4	O
%,	O
9	O
.	O
6	O
%,	O
and	O
2	O
.	O
7	O
%	O
increase	O
in	O
longitudinal	O
bone	O
growth	O
,	O
respectively	O
,	O
compared	O
with	O
control	O
,	O
suggesting	O
that	O
the	O
effect	O
decreases	O
downward	O
from	O
upper	O
section	O
to	O
the	O
base	O
.	O

Although	O
VAM	O
caused	O
slight	O
increase	O
in	O
longitudinal	O
bone	O
growth	O
,	O
statistical	O
significance	O
was	O
not	O
observed	O
.	O

The	O
present	O
study	O
provides	O
first	O
evidence	O
for	O
the	O
effectiveness	O
as	O
well	O
as	O
regional	O
differences	O
of	O
VA	O
on	O
longitudinal	O
bone	O
growth	O
in	O
adolescent	O
rats	B-OG
.	O

Recently	O
,	O
Tseng	O
et	O
al	O
.	O
[	O
19	O
]	O
compared	O
the	O
antiosteoporotic	O
activity	O
of	O
VA	O
from	O
different	O
sections	O
using	O
ovariectomy	O
-	O
induced	O
osteoporosis	B-DS
animal	B-OG
model	O
and	O
suggest	O
that	O
the	O
upper	O
and	O
middle	O
sections	O
of	O
VA	O
were	O
equally	O
effective	O
in	O
protecting	O
bones	O
from	O
an	O
estrogen	O
-	O
deficient	O
state	O
.	O

However	O
,	O
the	O
effects	O
on	O
proliferation	O
and	O
mineralization	O
of	O
osteoblasts	O
,	O
MC3T3	O
-	O
E1	O
cells	O
,	O
were	O
decreased	O
downward	O
from	O
upper	O
section	O
to	O
the	O
base	O
[	O
19	O
]	O
supporting	O
the	O
results	O
of	O
the	O
present	O
study	O
.	O

In	O
addition	O
they	O
reported	O
that	O
the	O
level	O
of	O
insulin	B-GP
-	I-GP
like	I-GP
growth	I-GP
factor	I-GP
1	I-GP
(	O
IGF	B-GP
-	I-GP
1	I-GP
)	O
was	O
decreased	O
downward	O
from	O
upper	O
section	O
to	O
base	O
section	O
.	O

Longitudinal	O
bone	O
growth	O
is	O
a	O
function	O
of	O
growth	O
plate	O
chondrocyte	O
proliferation	O
and	O
hypertrophy	O
,	O
and	O
IGF	B-GP
-	I-GP
1	I-GP
is	O
reputed	O
to	O
augment	O
longitudinal	O
bone	O
growth	O
by	O
stimulating	O
growth	O
plate	O
chondrocyte	O
proliferation	O
[	O
20	O
].	O

Therefore	O
,	O
these	O
data	O
support	O
the	O
results	O
of	O
the	O
present	O
study	O
,	O
and	O
one	O
of	O
the	O
possible	O
mechanisms	O
may	O
be	O
explained	O
by	O
the	O
IGF	B-GP
-	I-GP
1	I-GP
level	O
in	O
each	O
section	O
of	O
VA	O
.	O

3	O
.	O
2	O
.	O

Effects	O
on	O
Growth	O
Plate	O
Heights	O

The	O
growth	O
plate	O
,	O
which	O
is	O
located	O
at	O
the	O
distal	O
end	O
of	O
the	O
bone	O
,	O
is	O
the	O
main	O
location	O
where	O
longitudinal	O
bone	O
growth	O
occurs	O
owing	O
to	O
the	O
stimulation	O
of	O
chondrocyte	O
proliferation	O
.	O

The	O
growth	O
plate	O
consists	O
of	O
four	O
distinctive	O
histological	O
zones	O
beginning	O
with	O
the	O
resting	O
zone	O
and	O
extending	O
through	O
the	O
proliferative	O
,	O
hypertrophic	O
,	O
and	O
ossification	O
zones	O
(	O
Figure	O
3	O
(	O
a	O
)).	O

The	O
topmost	O
layer	O
,	O
the	O
resting	O
zone	O
,	O
contains	O
chondrocytes	O
that	O
serve	O
as	O
stem	O
-	O
like	O
cells	O
for	O
the	O
growth	O
plate	O
,	O
with	O
the	O
potential	O
to	O
generate	O
clones	O
of	O
rapidly	O
proliferating	O
chondrocytes	O
,	O
which	O
are	O
located	O
in	O
the	O
proliferative	O
zone	O
in	O
the	O
second	O
layer	O
of	O
the	O
growth	O
plate	O
[	O
21	O
].	O

The	O
proliferative	O
zone	O
is	O
the	O
driving	O
force	O
behind	O
bone	O
elongation	O
.	O

Over	O
time	O
,	O
as	O
longitudinal	O
growth	O
proceeds	O
,	O
proliferative	O
cells	O
close	O
to	O
the	O
hypertrophic	O
zone	O
undergo	O
terminal	O
differentiation	O
.	O

During	O
this	O
process	O
,	O
they	O
stop	O
proliferating	O
and	O
physically	O
enlarge	O
to	O
become	O
hypertrophic	O
chondrocytes	O
,	O
composing	O
the	O
third	O
,	O
hypertrophic	O
layer	O
of	O
the	O
growth	O
plate	O
.	O

In	O
the	O
ossification	O
zone	O
,	O
the	O
chondrocytes	O
eventually	O
die	O
and	O
are	O
transformed	O
into	O
bone	O
matrix	O
where	O
longitudinal	O
bone	O
growth	O
occurred	O
[	O
22	O
].	O

Since	O
the	O
synchronized	O
processes	O
of	O
chondrocyte	O
proliferation	O
and	O
cartilage	O
ossification	O
in	O
growth	O
plate	O
lead	O
to	O
longitudinal	O
bone	O
growth	O
[	O
23	O
],	O
the	O
rate	O
of	O
longitudinal	O
bone	O
growth	O
is	O
regulated	O
by	O
the	O
rate	O
of	O
chondrocyte	O
proliferation	O
of	O
the	O
growth	O
plate	O
[	O
24	O
].	O

In	O
the	O
present	O
study	O
,	O
the	O
rate	O
of	O
chondrocyte	O
proliferation	O
was	O
determined	O
by	O
measuring	O
the	O
height	O
of	O
the	O
proximal	O
tibia	O
growth	O
plate	O
(	O
Figure	O
3	O
(	O
a	O
)).	O

The	O
height	O
of	O
the	O
growth	O
plate	O
in	O
the	O
control	O
group	O
was	O
511	O
.	O
2	O
Â±	O
21	O
.	O
6	O
Î¼m	O
,	O
and	O
administration	O
of	O
100	O
mg	O
/	O
kg	O
VAU	O
and	O
VAM	O
significantly	O
increased	O
the	O
height	O
of	O
the	O
growth	O
plate	O
to	O
567	O
.	O
4	O
Â±	O
23	O
.	O
4	O
Î¼m	O
and	O
566	O
.	O
2	O
Â±	O
20	O
.	O
6	O
Î¼m	O
,	O
respectively	O
(	O
Figure	O
3	O
(	O
b	O
)).	O

The	O
effect	O
of	O
VAU	O
(	O
11	O
.	O
0	O
%)	O
was	O
similar	O
to	O
that	O
of	O
VAM	O
(	O
10	O
.	O
8	O
%),	O
while	O
VAB	O
caused	O
6	O
.	O
3	O
%	O
increase	O
which	O
was	O
not	O
statistically	O
significant	O
compared	O
with	O
control	O
.	O

These	O
results	O
suggest	O
that	O
the	O
effect	O
of	O
VAM	O
was	O
slightly	O
lower	O
but	O
not	O
statistically	O
significant	O
compared	O
with	O
VAU	O
,	O
and	O
the	O
effect	O
decreases	O
downward	O
from	O
upper	O
section	O
to	O
the	O
base	O
.	O

3	O
.	O
3	O
.	O

Effects	O
on	O
BMP	B-GP
-	I-GP
2	I-GP
Expression	O

BMPs	B-GP
play	O
important	O
roles	O
in	O
regulating	O
growth	O
plate	O
chondrogenesis	O
and	O
longitudinal	O
bone	O
growth	O
.	O

Of	O
the	O
various	O
forms	O
of	O
BMP	B-GP
,	O
BMP	B-GP
-	I-GP
2	I-GP
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
the	O
epiphyseal	O
growth	O
plate	O
[	O
25	O
].	O

BMP	B-GP
-	I-GP
2	I-GP
stimulates	O
chondrocyte	O
proliferation	O
in	O
the	O
proliferative	O
zone	O
of	O
the	O
growth	O
plate	O
and	O
also	O
causes	O
an	O
increase	O
in	O
chondrocyte	O
hypertrophy	O
[	O
26	O
].	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
suggested	O
that	O
alterations	O
in	O
the	O
expression	O
or	O
production	O
of	O
BMP	B-GP
-	I-GP
2	I-GP
can	O
modulate	O
the	O
proliferation	O
and	O
activity	O
of	O
bone	O
forming	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
protein	O
expression	O
of	O
BMP	B-GP
-	I-GP
2	I-GP
in	O
growth	O
plate	O
was	O
highly	O
expressed	O
in	O
hypertrophic	O
and	O
ossification	O
zones	O
compared	O
to	O
resting	O
and	O
proliferative	O
zones	O
(	O
Figure	O
4	O
(	O
a	O
)).	O

As	O
expected	O
,	O
BMP	B-GP
-	I-GP
2	I-GP
expressions	O
particularly	O
in	O
hypertrophic	O
and	O
ossification	O
zones	O
of	O
the	O
growth	O
plates	O
were	O
increased	O
in	O
the	O
VAU	O
and	O
VAM	O
treated	O
groups	O
compared	O
with	O
the	O
control	O
group	O
(	O
Figures	O
4	O
(	O
a	O
)	O
and	O
4	O
(	O
b	O
)).	O

Numerical	O
values	O
of	O
the	O
BMP	B-GP
-	I-GP
2	I-GP
expression	O
were	O
increased	O
by	O
25	O
.	O
8	O
%,	O
24	O
.	O
7	O
%,	O
and	O
10	O
.	O
5	O
%	O
with	O
VAU	O
,	O
VAM	O
,	O
and	O
VAB	O
treatment	O
,	O
respectively	O
,	O
compared	O
with	O
control	O
(	O
Figure	O
4	O
(	O
b	O
)).	O

The	O
effect	O
on	O
BMP	B-GP
-	I-GP
2	I-GP
expression	O
in	O
growth	O
plate	O
,	O
which	O
is	O
related	O
to	O
the	O
bone	O
growth	O
and	O
formation	O
,	O
was	O
also	O
decreased	O
downward	O
from	O
upper	O
section	O
to	O
the	O
base	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
VAM	O
was	O
similar	O
to	O
VAU	O
.	O

The	O
results	O
of	O
the	O
in	O
vivo	O
experiment	O
suggest	O
that	O
treatment	O
with	O
VA	O
increases	O
longitudinal	O
bone	O
growth	O
rate	O
by	O
promoting	O
chondrocyte	O
proliferation	O
and	O
chondrogenesis	O
through	O
the	O
upregulation	O
of	O
BMP	B-GP
-	I-GP
2	I-GP
expression	O
in	O
growth	O
plate	O
,	O
and	O
the	O
effect	O
decreases	O
downward	O
from	O
upper	O
section	O
to	O
the	O
base	O
.	O

3	O
.	O
4	O
.	O

Effects	O
on	O
MG63	O
Cell	O
Osteogenesis	O

Bone	O
regeneration	O
is	O
regulated	O
by	O
a	O
fine	O
balance	O
of	O
biochemical	O
and	O
cellular	O
events	O
that	O
ultimately	O
stimulate	O
osteoblasts	O
to	O
produce	O
new	O
tissue	O
,	O
in	O
particular	O
,	O
new	O
extracellular	O
matrix	O
composed	O
mainly	O
of	O
collagen	B-GP
.	O

The	O
collagen	B-GP
matrix	O
is	O
then	O
mineralized	O
via	O
ALP	B-GP
activity	O
,	O
which	O
induces	O
formation	O
of	O
calcium	O
phosphate	O
crystal	O
seeds	O
.	O

Bellows	O
et	O
al	O
.	O
[	O
27	O
]	O
reported	O
that	O
ALP	B-GP
is	O
one	O
of	O
the	O
osteoblast	O
phenotype	O
markers	O
and	O
an	O
essential	O
enzyme	O
for	O
mineralization	O
.	O

Hence	O
,	O
osteoblast	O
proliferation	O
,	O
collagen	B-GP
content	O
,	O
and	O
ALP	B-GP
activity	O
,	O
as	O
early	O
differentiation	O
markers	O
,	O
and	O
cellular	O
calcium	O
content	O
,	O
as	O
a	O
late	O
marker	O
of	O
differentiation	O
,	O
were	O
examined	O
to	O
investigate	O
the	O
effects	O
of	O
VA	O
on	O
the	O
differentiation	O
of	O
MG	O
-	O
63	O
cells	O
.	O

First	O
,	O
the	O
effect	O
of	O
different	O
sections	O
of	O
VA	O
on	O
osteoblast	O
proliferation	O
was	O
examined	O
by	O
BrdU	O
incorporation	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
a	O
),	O
MG	O
-	O
63	O
cell	O
proliferation	O
was	O
significantly	O
and	O
dose	O
-	O
dependently	O
increased	O
with	O
VAU	O
and	O
VAM	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

MG	O
-	O
63	O
cell	O
proliferation	O
reached	O
peak	O
value	O
at	O
50	O
Î¼g	O
/	O
mL	O
VAU	O
treatment	O
exhibiting	O
119	O
%	O
of	O
the	O
basal	O
value	O
,	O
while	O
VAM	O
treatment	O
reached	O
peak	O
at	O
100	O
Î¼g	O
/	O
mL	O
exhibiting	O
111	O
%	O
of	O
the	O
basal	O
value	O
.	O

VAB	O
at	O
the	O
highest	O
concentration	O
(	O
100	O
Î¼g	O
/	O
mL	O
)	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
increased	O
cell	O
proliferation	O
compared	O
to	O
the	O
control	O
exhibiting	O
106	O
%	O
of	O
the	O
basal	O
value	O
.	O

Effects	O
of	O
VAU	O
and	O
VAM	O
on	O
increasing	O
cell	O
proliferation	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
control	O
at	O
50	O
and	O
100	O
Î¼g	O
/	O
mL	O
concentration	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
VA	O
on	O
ALP	B-GP
activity	O
in	O
MG	O
-	O
63	O
cells	O
was	O
further	O
determined	O
at	O
50	O
and	O
100	O
Î¼g	O
/	O
mL	O
concentration	O
.	O

VAU	O
treatment	O
significantly	O
increased	O
the	O
ALP	B-GP
activity	O
,	O
an	O
early	O
-	O
stage	O
osteoblasts	O
differentiation	O
marker	O
,	O
at	O
100	O
Î¼g	O
/	O
mL	O
concentration	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
5	O
(	O
b	O
))	O
compared	O
with	O
control	O
.	O

VAM	O
and	O
VAB	O
failed	O
to	O
affect	O
ALP	B-GP
level	O
.	O

Hence	O
,	O
collagen	B-GP
content	O
(	O
Figure	O
5	O
(	O
c	O
))	O
and	O
calcium	O
deposition	O
(	O
Figure	O
5	O
(	O
d	O
))	O
were	O
determined	O
at	O
100Î¼g	O
/	O
mL	O
of	O
VA	O
concentration	O
.	O

Collagen	B-GP
synthesis	O
was	O
significantly	O
increased	O
with	O
VAU	O
(	O
11	O
.	O
2	O
%)	O
and	O
VAM	O
(	O
6	O
.	O
2	O
%)	O
treatment	O
compared	O
with	O
control	O
,	O
and	O
the	O
increased	O
collagen	B-GP
synthesis	O
was	O
significantly	O
higher	O
than	O
VAB	O
.	O

Cellular	O
calcium	O
deposition	O
was	O
examined	O
using	O
Alizarin	O
red	O
-	O
S	O
staining	O
.	O

Significant	O
increases	O
in	O
mineralization	O
were	O
found	O
with	O
VAU	O
and	O
VAM	O
treatment	O
compared	O
to	O
the	O
control	O
and	O
VAB	O
group	O
.	O

Mineralization	O
was	O
significantly	O
increased	O
to	O
118	O
%	O
and	O
107	O
%	O
of	O
the	O
control	O
by	O
VAU	O
and	O
VAM	O
treatment	O
,	O
respectively	O
.	O

The	O
anabolic	O
effect	O
of	O
VA	O
on	O
bone	O
was	O
further	O
supported	O
by	O
the	O
findings	O
in	O
this	O
study	O
demonstrating	O
that	O
VA	O
enhanced	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
mineralization	O
of	O
osteoblastic	O
cells	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
VAU	O
were	O
greater	O
than	O
the	O
effect	O
of	O
VAM	O
,	O
suggesting	O
that	O
the	O
effects	O
were	O
decreased	O
from	O
the	O
upper	O
section	O
to	O
the	O
base	O
section	O
.	O

Lee	O
et	O
al	O
.	O
[	O
28	O
]	O
reported	O
that	O
VA	O
water	O
extract	O
enhanced	O
osteoblasts	O
proliferation	O
and	O
mineralization	O
.	O

Furthermore	O
,	O
Tseng	O
et	O
al	O
.	O
[	O
19	O
]	O
reported	O
that	O
VAU	O
and	O
VAM	O
dose	O
-	O
dependently	O
increased	O
osteoblasts	O
proliferation	O
as	O
well	O
as	O
mineralization	O
supporting	O
the	O
results	O
of	O
the	O
present	O
study	O
.	O

3	O
.	O
5	O
.	O

Effects	O
on	O
Osteogenic	O
Gene	O
Expression	O

It	O
is	O
known	O
that	O
preosteoblastic	O
cells	O
produce	O
proteins	O
of	O
the	O
extracellular	O
matrix	O
including	O
collagen	B-GP
at	O
first	O
and	O
then	O
to	O
successively	O
produce	O
alkaline	B-GP
phosphatase	I-GP
(	O
ALP	B-GP
)	O
and	O
osteopontin	B-GP
/	O
osteocalcin	B-GP
during	O
mineralization	O
phase	O
[	O
29	O
].	O

Accordingly	O
,	O
there	O
is	O
increased	O
expression	O
of	O
osteogenic	O
genes	O
in	O
osteoblasts	O
during	O
the	O
bone	O
formation	O
process	O
,	O
and	O
these	O
genes	O
play	O
roles	O
in	O
extracellular	O
matrix	O
formation	O
and	O
mineral	O
deposition	O
.	O

Collagen	B-GP
(	O
COL	B-GP
)	O
is	O
a	O
primary	O
gene	O
product	O
of	O
osteoblasts	O
during	O
bone	O
matrix	O
formation	O
and	O
comprises	O
85	O
â€“	O
90	O
%	O
of	O
the	O
total	O
organic	O
bone	O
matrix	O
[	O
30	O
].	O

Noncollagenous	O
matrix	B-GP
proteins	I-GP
also	O
have	O
a	O
great	O
importance	O
in	O
regulating	O
of	O
ossification	O
and	O
bone	O
remodeling	O
.	O

The	O
most	O
abundant	O
noncollagenous	O
protein	O
produced	O
by	O
osteoblasts	O
is	O
osteocalcin	B-GP
(	O
OCN	B-GP
),	O
a	O
phosphorylated	O
glycoprotein	O
which	O
has	O
high	O
affinity	O
for	O
binding	O
ionic	O
calcium	O
and	O
physiologic	O
hydroxyapatite	O
[	O
31	O
].	O

Osteopontin	B-GP
(	O
OPN	B-GP
)	O
is	O
an	O
osteoblast	O
-	O
derived	O
,	O
heavily	O
glycosylated	O
protein	O
of	O
the	O
bone	O
matrix	O
,	O
which	O
is	O
expressed	O
at	O
late	O
stages	O
of	O
differentiation	O
,	O
and	O
its	O
appearance	O
closely	O
correlates	O
with	O
the	O
appearance	O
of	O
mineral	O
[	O
31	O
].	O

In	O
order	O
to	O
examine	O
the	O
anabolic	O
effect	O
of	O
VA	O
,	O
the	O
mRNA	O
expressions	O
of	O
COL	B-GP
,	O
ALP	B-GP
,	O
OCN	B-GP
,	O
and	O
OPN	B-GP
in	O
MG	O
-	O
63	O
cells	O
were	O
measured	O
by	O
real	O
-	O
time	O
PCR	O
(	O
Figure	O
6	O
).	O

All	O
sections	O
of	O
the	O
VA	O
(	O
VAU	O
,	O
VAM	O
,	O
and	O
VAB	O
)	O
treatment	O
caused	O
marked	O
upregulation	O
of	O
COL	B-GP
and	O
OCN	B-GP
mRNA	O
levels	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
VAM	O
and	O
VAB	O
were	O
not	O
significantly	O
different	O
from	O
the	O
effect	O
of	O
VAU	O
in	O
COL	B-GP
and	O
OCN	B-GP
expressions	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
effects	O
of	O
VAU	O
,	O
VAM	O
,	O
and	O
VAB	O
on	O
COL	B-GP
mRNA	O
expressions	O
were	O
increased	O
7	O
.	O
7	O
-,	O
6	O
.	O
0	O
-,	O
and	O
5	O
.	O
8	O
-	O
fold	O
,	O
respectively	O
,	O
while	O
those	O
of	O
OCN	B-GP
expressions	O
were	O
increased	O
22	O
.	O
5	O
-,	O
20	O
.	O
2	O
-,	O
and	O
15	O
.	O
0	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
expressions	O
of	O
ALP	B-GP
mRNA	O
were	O
significantly	O
increased	O
with	O
VAU	O
(	O
3	O
.	O
7	O
-	O
fold	O
)	O
and	O
VAM	O
(	O
3	O
.	O
5	O
-	O
fold	O
)	O
treatment	O
compared	O
with	O
control	O
and	O
VAB	O
group	O
(	O
1	O
.	O
2	O
-	O
fold	O
).	O
OPN	B-GP
mRNA	O
expressions	O
were	O
not	O
altered	O
by	O
all	O
sections	O
of	O
VA	O
.	O

These	O
data	O
suggest	O
that	O
VA	O
may	O
play	O
role	O
at	O
early	O
stage	O
as	O
well	O
as	O
late	O
stage	O
of	O
osteoblast	O
differentiation	O
,	O
and	O
VA	O
-	O
induced	O
COL	B-GP
,	O
ALP	B-GP
,	O
and	O
OCN	B-GP
gene	O
expression	O
could	O
accelerate	O
mineralization	O
,	O
subsequently	O
leading	O
to	O
an	O
increase	O
in	O
the	O
extent	O
of	O
calcium	O
deposition	O
.	O

Furthermore	O
,	O
the	O
effects	O
on	O
osteogenic	O
gene	O
expressions	O
were	O
decreased	O
from	O
upper	O
section	O
to	O
basal	O
section	O
of	O
VA	O
,	O
and	O
the	O
effect	O
of	O
VAM	O
was	O
similar	O
to	O
VAU	O
.	O

Lee	O
et	O
al	O
.	O
[	O
28	O
]	O
reported	O
that	O
VA	O
increased	O
mRNA	O
expression	O
of	O
bone	B-GP
sialoprotein	I-GP
which	O
is	O
related	O
to	O
bone	O
mineralization	O
.	O

3	O
.	O
6	O
.	O

Effects	O
on	O
Osteoclastogenesis	O

Osteoclasts	O
are	O
the	O
only	O
cell	O
type	O
capable	O
of	O
resorbing	O
mineralized	O
bone	O
.	O

To	O
examine	O
the	O
effect	O
of	O
VA	O
on	O
osteoclast	O
differentiation	O
,	O
bone	O
marrow	O
-	O
derived	O
osteoclast	O
precursor	O
cells	O
were	O
cultured	O
in	O
osteoclastogenic	O
media	O
with	O
different	O
parts	O
of	O
VA	O
extract	O
.	O

TRAP	B-GP
-	O
positive	O
multinuclear	O
osteoclasts	O
were	O
generated	O
in	O
response	O
to	O
stimulation	O
from	O
M	B-GP
-	I-GP
CSF	I-GP
and	O
RANKL	B-GP
.	O

The	O
results	O
showed	O
that	O
the	O
addition	O
of	O
VA	O
did	O
not	O
affect	O
osteoclast	O
formation	O
(	O
data	O
not	O
shown	O
).	O
Bacillus	B-OG
-	O
fermented	O
VA	O
extract	O
has	O
been	O
reported	O
to	O
inhibit	O
osteoclast	O
differentiation	O
[	O
32	O
]	O
which	O
does	O
not	O
support	O
the	O
results	O
of	O
the	O
present	O
study	O
.	O

However	O
,	O
Lee	O
et	O
al	O
.	O
[	O
28	O
]	O
suggested	O
that	O
VA	O
,	O
fermented	O
with	O
Cordyceps	B-OG
militaris	I-OG
,	O
contain	O
more	O
sialic	O
acid	O
than	O
nonfermented	O
VA	O
,	O
and	O
the	O
stimulatory	O
effects	O
on	O
osteoblastic	O
cell	O
proliferation	O
and	O
ALP	B-GP
production	O
were	O
increased	O
by	O
fermentation	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
nonfermented	O
VA	O
in	O
the	O
present	O
study	O
may	O
not	O
be	O
strong	O
enough	O
to	O
induce	O
osteoclast	O
differentiation	O
.	O

4	O
.	O

Conclusions	O

In	O
conclusion	O
,	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
VA	O
promotes	O
longitudinal	O
bone	O
growth	O
in	O
adolescent	O
rats	B-OG
through	O
,	O
at	O
least	O
in	O
part	O
,	O
MG	O
-	O
63	O
cell	O
osteogenesis	O
,	O
and	O
the	O
effect	O
was	O
decreased	O
downward	O
from	O
upper	O
section	O
to	O
basal	O
section	O
.	O

VA	O
stimulated	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
mineralization	O
of	O
osteoblasts	O
through	O
upregulation	O
of	O
osteogenic	O
gene	O
expressions	O
.	O

These	O
results	O
support	O
the	O
stimulating	O
nature	O
of	O
VA	O
toward	O
the	O
function	O
of	O
osteoblastic	O
cells	O
.	O

Although	O
the	O
molecular	O
mechanisms	O
underlying	O
osteoblast	O
differentiation	O
remain	O
to	O
be	O
defined	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
BMP	B-GP
-	I-GP
2	I-GP
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
osteoblast	O
differentiation	O
and	O
subsequent	O
bone	O
formation	O
,	O
might	O
participate	O
in	O
these	O
mechanisms	O
.	O

Furthermore	O
,	O
the	O
present	O
study	O
provides	O
strong	O
evidence	O
for	O
the	O
regional	O
differences	O
in	O
the	O
effectiveness	O
of	O
VA	O
in	O
longitudinal	O
bone	O
growth	O
.	O

However	O
,	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
bioactive	O
chemical	O
constituents	O
associated	O
with	O
these	O
effects	O
.	O

The	O
present	O
study	O
has	O
some	O
limitations	O
.	O

Only	O
a	O
single	O
dose	O
of	O
VA	O
was	O
used	O
in	O
the	O
in	O
vivo	O
study	O
.	O

The	O
dose	O
for	O
traditional	O
use	O
of	O
VA	O
is	O
usually	O
1	O
g	O
/	O
day	O
,	O
taken	O
all	O
at	O
once	O
or	O
divided	O
throughout	O
the	O
day	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
/	O
day	O
given	O
to	O
the	O
experimental	O
rats	B-OG
in	O
this	O
study	O
was	O
equivalent	O
to	O
the	O
traditional	O
human	B-OG
dosing	O
regimen	O
of	O
1	O
g	O
/	O
day	O
based	O
on	O
body	O
surface	O
area	O
conversion	O
,	O
where	O
animal	B-OG
dose	O
is	O
equal	O
to	O
human	B-OG
equivalent	O
dose	O
Ã—	O
6	O
.	O
2	O
,	O
assuming	O
that	O
an	O
adult	O
person	O
'	O
s	O
weight	O
is	O
60	O
kg	O
[	O
33	O
].	O

Sections	O
of	O
velvet	O
antler	O
.	O

Fresh	O
velvet	O
antler	O
was	O
divided	O
into	O
upper	O
(	O
VAU	O
),	O
middle	O
(	O
VAM	O
),	O
and	O
basal	O
(	O
VAB	O
)	O
sections	O
.	O

Effects	O
of	O
velvet	O
antler	O
on	O
longitudinal	O
bone	O
growth	O
.	O

(	O
a	O
)	O
Fluorescence	O
photomicrographs	O
of	O
longitudinal	O
sections	O
of	O
the	O
proximal	O
tibias	O
of	O
control	O
and	O
VAU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
treated	O
rats	O
.	O

(	O
b	O
)	O
Numerical	O
values	O
of	O
longitudinal	O
bone	O
growth	O
.	O

The	O
arrow	O
between	O
the	O
fluorescent	O
line	O
formed	O
by	O
calcein	O
(	O
lower	O
arrow	O
)	O
and	O
the	O
epiphyseal	O
end	O
line	O
of	O
the	O
growth	O
plate	O
(	O
upper	O
arrow	O
)	O
indicates	O
the	O
bone	O
growth	O
during	O
the	O
24	O
h	O
period	O
.	O

VAU	O
:	O
upper	O
section	O
of	O
VA	O
;	O
VAM	O
:	O
middle	O
section	O
of	O
VA	O
;	O
VAB	O
:	O
basal	O
section	O
of	O
VA	O
.	O

The	O
data	O
are	O
expressed	O
as	O
means	O
Â±	O
SD	O
.	O

The	O
bars	O
with	O
a	O
different	O
letter	O
are	O
significantly	O
different	O
from	O
each	O
other	O
at	O
the	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

Effects	O
of	O
velvet	O
antler	O
on	O
growth	O
plate	O
height	O
.	O

(	O
a	O
)	O
Cresyl	O
violet	O
stained	O
sections	O
of	O
tibial	O
growth	O
plates	O
of	O
control	O
and	O
VAU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
treated	O
rats	O
.	O

(	O
b	O
)	O
Numerical	O
values	O
of	O
growth	O
plate	O
height	O
.	O

Upper	O
arrow	O
indicates	O
the	O
resting	O
zone	O
where	O
quiescent	O
chondrocytes	O
are	O
waiting	O
for	O
the	O
proliferation	O
of	O
the	O
growth	O
plates	O
,	O
and	O
lower	O
arrow	O
indicates	O
the	O
ossification	O
zone	O
where	O
cartilaginous	O
matrix	O
begins	O
to	O
calcify	O
and	O
replace	O
with	O
mineralized	O
bone	O
tissue	O
.	O

VAU	O
:	O
upper	O
section	O
of	O
VA	O
;	O
VAM	O
:	O
middle	O
section	O
of	O
VA	O
;	O
VAB	O
:	O
basal	O
section	O
of	O
VA	O
.	O

The	O
data	O
are	O
expressed	O
as	O
means	O
Â±	O
SD	O
.	O

Values	O
not	O
sharing	O
a	O
common	O
alphabet	O
are	O
significantly	O
different	O
from	O
each	O
other	O
at	O
the	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

Effects	O
of	O
velvet	O
antler	O
on	O
BMP	O
-	O
2	O
expression	O
.	O

(	O
a	O
)	O
Immunohistochemical	O
localizations	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
(	O
BMP	O
-	O
2	O
)	O
in	O
the	O
growth	O
plates	O
of	O
control	O
and	O
VAU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
treated	O
rats	O
.	O

(	O
b	O
)	O
Densitometric	O
results	O
of	O
immunohistochemistry	O
.	O

VAU	O
:	O
upper	O
section	O
of	O
VA	O
;	O
VAM	O
:	O
middle	O
section	O
of	O
VA	O
;	O
VAB	O
:	O
basal	O
section	O
of	O
VA	O
.	O

Data	O
are	O
shown	O
as	O
a	O
percentage	O
of	O
the	O
control	O
value	O
(	O
means	O
Â±	O
SD	O
).	O

Values	O
not	O
sharing	O
a	O
common	O
alphabet	O
are	O
significantly	O
different	O
from	O
each	O
other	O
at	O
the	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

Effects	O
of	O
velvet	O
antler	O
on	O
cell	O
proliferation	O
(	O
a	O
),	O
alkaline	O
phosphatase	O
activity	O
(	O
b	O
),	O
collagen	O
synthesis	O
(	O
c	O
),	O
and	O
calcium	O
deposit	O
(	O
d	O
)	O
in	O
MG	O
-	O
63	O
human	O
osteoblast	O
-	O
like	O
cells	O
.	O

VAU	O
:	O
upper	O
section	O
of	O
VA	O
;	O
VAM	O
:	O
middle	O
section	O
of	O
VA	O
;	O
VAB	O
:	O
basal	O
section	O
of	O
VA	O
.	O

Data	O
are	O
shown	O
as	O
a	O
percentage	O
of	O
the	O
control	O
value	O
(	O
means	O
Â±	O
SD	O
)	O
of	O
the	O
three	O
cultures	O
.	O

Values	O
not	O
sharing	O
a	O
common	O
alphabet	O
are	O
significantly	O
different	O
from	O
each	O
other	O
at	O
the	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

Effects	O
of	O
velvet	O
antler	O
on	O
osteogenic	O
gene	O
expression	O
in	O
MG	O
-	O
63	O
cells	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
measure	O
mRNA	O
levels	O
following	O
VA	O
treatment	O
.	O

Expression	O
of	O
GAPDH	O
was	O
used	O
to	O
normalize	O
all	O
samples	O
.	O

(	O
a	O
)	O
Collagen	O
(	O
COL	O
).	O

(	O
b	O
)	O
Alkaline	O
phosphatase	O
(	O
ALP	O
).	O

(	O
c	O
)	O
Osteocalcin	O
(	O
OCN	O
).	O

(	O
d	O
)	O
Osteopontin	O
(	O
OPN	O
).	O

Data	O
are	O
shown	O
as	O
a	O
fold	O
of	O
the	O
control	O
value	O
(	O
means	O
Â±	O
SD	O
)	O
of	O
the	O
three	O
cultures	O
.	O

Values	O
not	O
sharing	O
a	O
common	O
alphabet	O
are	O
significantly	O
different	O
from	O
each	O
other	O
at	O
the	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
.	O

Oligonucleotide	O
sequences	O
of	O
osteogenic	O
genes	O
.	O

Primer	O

Direction	O

Sequence	O

Collagen	O
(	O
COL	O
)	O

Forward	O

5	O
â€²-	O
GCG	O
GCT	O
CCC	O
CAT	O
TTT	O
TAT	O
ACC	O
-	O
3	O
â€²	O

Reverse	O

5	O
â€²-	O
GCT	O
CTC	O
CTC	O
CCA	O
TGT	O
TAA	O
ATA	O
GCA	O
-	O
3	O
â€²	O


Alkaline	O
phosphatase	O
(	O
ALP	O
)	O

Forward	O

5	O
â€²-	O
AAA	O
CCG	O
AGA	O
TAC	O
AAG	O
CAC	O
TCC	O
CAC	O
-	O
3	O
â€²	O

Reverse	O

5	O
â€²-	O
TCC	O
GTC	O
ACG	O
TTG	O
TTC	O
CTG	O
TTC	O
AG	O
-	O
3	O
â€²	O


Osteocalcin	O
(	O
OCN	O
)	O

Forward	O

5	O
â€²-	O
CCA	O
TGA	O
GAG	O
CCC	O
TCA	O
CAC	O
TCC	O
TC	O
-	O
3	O
â€²	O

Reverse	O

5	O
â€²-	O
GCT	O
TGG	O
ACA	O
CAA	O
AGG	O
CTG	O
CAC	O
-	O
3	O
â€²	O


Osteopontin	O
(	O
OPN	O
)	O

Forward	O

5	O
â€²-	O
AGG	O
CTG	O
ATT	O
CTG	O
GAA	O
GTT	O
CTG	O
AGG	O
-	O
3	O
â€²	O

Reverse	O

5	O
â€²-	O
GAC	O
TTA	O
CTT	O
GGA	O
AGG	O
GYC	O
TGT	O
GGG	O
-	O
3	O
â€²	O


GAPDH	O

Forward	O

5	O
â€²-	O
TCA	O
TCA	O
ATG	O
GAA	O
ATC	O
CCA	O
TCA	O
CC	O
-	O
3	O
â€²	O

Reverse	O

5	O
â€²-	O
TGG	O
ACT	O
CCA	O
CGA	O
CGT	O
ACT	O
CAG	O
C	O
-	O
3	O
â€²	O

